Genentech Unveils First and Only TNKase® for Acute Ischaemic Stroke Management
Genentech has unveiled TNKase® (tenecteplase) as a new treatment option for acute ischaemic stroke (AIS) in adults, making it the first and only single-bolus thrombolytic therapy approved for AIS in the United States.
TNKase is a thrombolytic agent designed to dissolve blood clots. It is administered as a single five-second intravenous (IV) bolus, offering a faster and simpler alternative to Activase, which requires both an IV bolus and a 60-minute infusion.
To support its use in AIS, Genentech will introduce a new 25 mg vial configuration in the coming months.
Stroke remains a major health concern, ranking as the fifth leading cause of death and the primary cause of long-term disability in the United States.
With more than 795,000 people affected each year, timely treatment is essential, as brain damage occurs rapidly during an AIS. Immediate intervention is critical to minimise irreversible damage.
With its approval in AIS, the availability of TNKase expands treatment options for thrombolysis, potentially enhancing stroke care accessibility across different healthcare settings.
The treatment is recommended to be administered as soon as possible and within three hours of stroke symptom onset.
